You are here

IDF Urges FDA to Exempt Immunoglobulin from Biosimilars Pathway

Immune Deficiency Foundation urges FDA to exempt immunoglobulin from biosimilars pathway. Biosimilar testing should protect the safety of patients with primary immunodeficiency diseases.



CLICK HERE to read more.

News Category: